When low-dose tacrolimus CEP-grade API is specified for immediate-release oral capsule manufacture, the primary process sequence is dry blending, lubrication, and automatic capsule filling under controlled room humidity. The compound is micronized and pre-dispersed by geometric dilution because the label-claim mass per unit—0.5 mg, 1 mg, or 5 mg—falls below the threshold at which simple V-blender loading without staged mixing can produce content uniformity failure under USP <905> and Ph. Eur. 2.9.40. The addition ratio in the finished powder bed is governed by total fill weight: for a 100 mg to 300 mg capsule fill, tacrolimus content ranges from 0.17% w/w to 5.0% w/w, while the proportion of lactose monohydrate, hypromellose, croscarmellose sodium, and magnesium stearate is adjusted to maintain flow, disintegration, and dissolution. Processing on a dosator-type capsule filler at 20,000–80,000 capsules/h requires pre-dried API and excipients with loss on drying below 2.0% w/w; ambient relative humidity above 40% has been associated with powder adherence to filling tooling and weight variation drift in commercial batches. Dissolution is controlled by USP <711> Apparatus II at 50 RPM in 900 mL of a surfactant-containing aqueous medium selected according to the product-specific monograph, while blend uniformity acceptance typically uses stratified sampling with an RSD not exceeding 5.0%. The terminal finished dosage form is an immediate-release hard gelatin or HPMC capsule in 0.5 mg, 1 mg, and 5 mg strengths, packaged in blister with desiccant; this configuration is used for induction and maintenance immunosuppression after solid organ transplantation. The CEP-grade API must comply with the Ph. Eur. monographs for tacrolimus monohydrate and tacrolimus capsules, ICH Q3D elemental impurity limits, and residual solvent limits under ICH Q3C.

What Limits Hypromellose Matrix Swelling in Once-Daily Tacrolimus Tablets?

Prolonged-release tacrolimus tablets in 0.75 mg, 1 mg, and 4 mg strengths are produced by embedding the API in a swelling-controlled matrix, typically with hypromellose 2208 or 2910 at 20% to 40% of core weight. Because tacrolimus is a narrow-therapeutic-index compound, the matrix polymer content cannot be increased without risk of over-prolonged release, and too little polymer can produce dose-dumping; dissolution profiles are therefore compared to a reference product using similarity factor f2 across 12 or more time points under USP <711> and Ph. Eur. 2.9.3. The addition ratio of API is lower than in immediate-release capsules: for a 150 mg tablet core, tacrolimus represents 0.5% to 2.7% w/w, while fillers such as lactose monohydrate and microcrystalline cellulose are reduced to accommodate the rate-controlling polymer. Manufacture begins with micronized tacrolimus dispersed in an alcoholic granulating fluid and sprayed onto a lactose-based substrate in a fluid-bed granulator; granules are dried to a moisture content below 2.0% w/w, milled through a 1.0 mm screen, lubricated with magnesium stearate at 0.5%–1.0% w/w, and compressed on a rotary tablet press at 8–14 kN compression force. Tablet hardness is normally maintained between 40 N and 80 N, with friability not more than 1.0% w/w per Ph. Eur. 2.9.7. Magnesium stearate blend time after lubrication is kept below 5 min because excessive lubricant coating of hypromellose particles reduces gel-layer formation and can slow release. Film coating with an aqueous dispersion is acceptable when inlet air temperature is kept below 55°C and coating weight gain is controlled at 2%–4% w/w to avoid altering release kinetics. A documented incompatibility is the combination of tacrolimus with polyethylene oxide or high levels of croscarmellose in a matrix tablet; this can produce erratic release and premature drug leaching. Terminal finished products are prolonged-release tablets for once-daily oral administration, intended for patients stabilized on immediate-release therapy and converted under physician supervision; they are not interchangeable with immediate-release capsules without bioequivalence data.

In pediatric and clinically unstable patients for whom capsule swallowing is not reliable, tacrolimus granules for oral suspension are manufactured as single-dose sachets containing 0.2 mg or 1.0 mg tacrolimus per sachet. The dosage form is critical because the API content in the filled granule bed can be as low as 0.02% w/w, which places severe constraints on blend uniformity and segregation control. The addition ratio is controlled by starting with a screened lactose monohydrate carrier, adding a 1:10 pre-blend of micronized tacrolimus and carrier, and then further diluting in a tumble blender to final mass; croscarmellose sodium is included below 1.0% w/w and magnesium stearate below 0.5% w/w. Compliance is anchored to Ph. Eur. 2.9.40 uniformity of dosage units, Ph. Eur. 2.9.5 mass uniformity for single-dose sachets, and the relevant national paediatric-use registration requirements, with dissolution tested by USP <711> or Ph. Eur. 2.9.3 after reconstitution. The downstream production process uses low-shear tumble mixing rather than high-shear granulation because the low drug load and fine particle size of tacrolimus make wet granulation difficult to control without loss of potency; particle size enlargement is limited to dry roller compaction when necessary, followed by sieving through a 1.0 mm mesh and filling on an auger-type stick-pack machine. Fill mass variation is typically controlled within ±5.0% of target, and in-process loss on drying is maintained below 2.0% w/w to prevent cohesive granules from causing sachet weight drift. Terminal finished products are foil-laminate sachets of granules that are reconstituted in water to a 10 mL oral suspension immediately before administration; the formulation is not suitable for preparing multi-day liquid stockpiles because an aqueous suspension is not physically stable for prolonged storage.

Aseptic Fill-Finish of 5 mg/mL Tacrolimus Concentrate for Intravenous Infusion

A sterile injectable concentrate is manufactured at 5 mg/mL tacrolimus in a vehicle of 200 mg/mL polyoxyl 60 hydrogenated castor oil and 80% v/v dehydrated alcohol, with nitrogen overlay to minimize oxidative degradation. The formulation addition ratio is fixed by the low aqueous solubility of tacrolimus; the surfactant-ethanol vehicle is required to maintain the API in solution, and any reduction in polyoxyl 60 hydrogenated castor oil below the registered concentration risks precipitation upon dilution. The process is aseptic rather than terminally sterilized because tacrolimus is heat-sensitive; a 0.45 µm prefilter followed by a 0.22 µm PVDF or polyethersulfone sterilizing filter is used after bulk solution mixing, and the solution is filled into USP Type I glass ampoules or vials under unidirectional airflow in an EU GMP Annex 1 cleanroom. Compliance includes USP <71> sterility testing, USP <85> bacterial endotoxins, USP <788> particulate matter, Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, and ICH Q2(R1) analytical validation. During filtration, the surfactant content causes foaming and slow flux; filter integrity is tested before and after use, and filling lines require cleaning procedures capable of removing the oily vehicle. The concentrate is not injected directly; it is diluted into 0.9% sodium chloride injection or 5% dextrose injection before infusion to a final concentration typically between 0.004 mg/mL and 0.02 mg/mL. Incompatibility with PVC containers should be assessed because the surfactant can promote DEHP extraction; non-PVC or DEHP-free infusion sets are used for administration. Terminal finished product types include 1 mL and 2 mL ampoules or vials containing 5 mg and 10 mg tacrolimus respectively, for intravenous use in transplant induction and management.

Direct compression of immediate-release tacrolimus tablets is justified only where the API is pre-milled, the filler system prevents segregation, and the tablet core is kept small enough to support low-dose uniformity. The tablet core generally contains 0.5 mg, 1 mg, or 5 mg tacrolimus with a total core mass of 80 mg to 200 mg; the addition ratio of API therefore ranges from 0.25% w/w to 6.25% w/w. The lower end requires micronized active and staged geometric blending to satisfy USP <905> and Ph. Eur. 2.9.40 content uniformity. The filler system consists of lactose monohydrate, microcrystalline cellulose, and pregelatinized starch; disintegrant content is kept below 3.0% w/w to avoid rapid moisture uptake. Tablet manufacture runs on a rotary press at 30–60 RPM with compression force adjusted to 6–12 kN, and tablets are film-coated with an aqueous hypromellose-based coating at 2%–3% w/w weight gain. Hardness is maintained between 40 N and 80 N, and disintegration time is not more than 15 min in 900 mL water at 37°C per Ph. Eur. 2.9.1. The immediate-release tablet is a conventional oral solid dosage form for transplant immunosuppression, but it is not considered equivalent to prolonged-release tablets; therapeutic substitution is prohibited without bioequivalence data and physician supervision. Published data for specific generic direct-compression tacrolimus formulations is limited, but the process route is well-established in pharmaceutical manufacturing for low-dose, poorly water-soluble APIs.